Lasa Supergenerics Limited (NSEI: LASA)
Health Care · Pharmaceuticals · IN
Rs7.20
-2.83% today · -21.3% 1Y
Lasa Supergenerics Limited (NSEI: LASA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.77M and employs 77 people.
Over the last twelve months the share price has lost 21.3%, trading between 5.67 and 14.08.
Tweenvest scores Lasa Supergenerics Limited across four factors: quality 53/100, value 57/100, growth 0/100. Its strongest factor is value.
LASA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.77M
- Revenue (TTM)
- $689.56K
- P/E
- —
- EPS
- -3.30
- Dividend yield
- —
- Beta (5Y)
- 0.62
- 52-week high
- Rs14.08
- 52-week low
- Rs5.67
- Avg volume (3M)
- —
- Shares outstanding
- 50.10M
- Employees
- 77
- Next earnings
- —
About Lasa Supergenerics Limited
Lasa Supergenerics Limited, founded in 2016 and based in Mumbai, India, specializes in the development, manufacturing, and commercialization of various healthcare products for both human and animal well-being. Its operations predominantly cater to the Indian domestic market, though the firm also distributes its offerings internationally. The company's product portfolio includes active pharmaceutical ingredients (APIs) for veterinary applications and other uses, as well as anthelmintic drugs, ingredients for animal feed, and specialized reagents employed in therapeutic treatments.
- ISIN
- INE670X01014
- Founded
- 2016
- Listed since
- Sep 21, 2017
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.